John Lewis, PhD
Founder and CEO of Entos Pharmaceuticals, Nanostics, OncoSenX, Aegis Life Inc. and Associate Professor of Oncology, University of Alberta

Dr. John Lewis is CEO of Entos Pharmaceuticals, an Edmonton-based biotechnology company developing genetic medicines using the Fusogenix drug delivery system. Entos is developing DNA-based vaccine and therapeutic countermeasures for COVID-19 using the Fusogenix platform technology.

Dr. Lewis holds the Frank and Carla Sojonky Chair in Prostate Cancer Research at the University of Alberta and is a Professor in the Department of Oncology, where he chairs the Alberta Prostate Cancer Research Initiative. Dr. John Lewis’s research interests lie in the areas of nanotechnology and imaging as they relate to infectious disease as well as chronic diseases such as aging and cancer. His group is focused mainly on the study of the spread, or metastasis, of cancer using advanced live imaging techniques.